|What am I going to do now, Nelson?
Aug 6, 2010
Hi Nelson, I hope all is well. Last year you told me about the trial with ibalizumab at ACRIA and I received the meds for about 1 year. In the beginning of thet trial the virus became undectadable but then it started to go up again and they took me out of the study. I was in the trial for about 1 year. My doctor changed my regimen to recycle meds…I’m resistant to all of them. I am now on Aptivus, Viread, Norvir and Trizivir. Do you know of any other trials in NYC? Thanks for your help.
|Response from Mr. Vergel
I am so sorry that your virus developed resistance to ibalizumab (Taimed’s intravenous CD4 monoclonal antibody that may be given once every two weeks).
I am working with ACRIA and two San Francisco doctors in setting up a small expanded access pilot to combine two investigational agents by early summer 2011, but we are still waiting for data. But it is not a done deal. However, one of the drugs may be ibalizumab.
GSK-ViiV are testing a second generation integrase inhibitor (GSK572) in phase II now and we are really hoping it can help people with raltegravir resistance. Some preliminary data show that it may help those with certain integrase mutations. GSK is also testing two non nucleosides in early phase 2. So, it will take at least 8 months to know where we are going with these agents.
AVEXA, an Australian company that has an interesting nucleoside, may be back in the picture after their board reconsidered not dropping their drug due to activist pressure. I am following that drug closely also.
BMS seems to have an entry inhibitor but they are a company that does not like to share information with treatment activists, so it has been a challenge to get them to tell us anything. It is unfortunate that in 2010 we still have this lack of communication going (but they are rare among companies).
Progenics also had a once a week subcutaneous entry inhibitor that looks very exciting. They are also a company that has refused to meet with treatment activists. They are small and may not understand the power that activists have in the present to help advocate for new drugs.
Koronis (http://www.koronispharma.com/KP1461forHIV.html) also has an interesting nucleoside that works very differently than the ones we have right now, but they have not tested it in people like you with a failing regimen.
Some of these companies may or may not agree to provide drug in a compassionate manner for one patient (but remember that you need at least two new active drugs to avoid functional monotherapy). But if your doctor wants to ask them, the FDA has set up a way to do so provided that the companies are willing to help. The FDA procedure is http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm163982.htm
Chemical engineer, 34+ year HIV and cancer survivor, health author and educator . Founder of DiscountedLabs.com , ExcelMale.com , and PowerUSA.org
This link has a video of an interview with Tim Brown, the man who got cured of HIV (who... read more
From the book: Built to Survive 12. Complementary Approaches to Treating Lipodystrophy By Michael Mooney (original version in Medibolics 2(2),Nov. 1997) While the... read more
Can Facial/Buttock Wasting Reconstruction Costs be Deducted from US Income Taxes?Someone was nice enough to do some research on... read more
Caribbean cruise and retreatThe combined gay and hetero Caribbean Positive Cruise is scheduled for October 10–18, and expects to... read more
FREE WORSKSHOP Program for Wellness Restoration, the Houston Buyers Club and LIVE Consortium present What to Do Now that You are Living Longer? How... read more
From: “News at The Body” <email@example.com> Date: 02 Aug 2011 17:55:01 -0400 To: <firstname.lastname@example.org> ReplyTo: “News at The... read more
I am so glad people are taking about this now. We are living longer and aging-related problems seems to... read more
CROI 2016 Conference Abstract Number: 795 Safety of Tenofovir Alafenamide in Renal Impairment Author(s): Anton Pozniak2, Jose R Arribas3, Samir K. Gupta4, Frank A.... read more
Sent via Blackberry From: “News at The Body” <email@example.com> Date: 05 Oct 2010 12:17:12 -0400 To: <firstname.lastname@example.org> ReplyTo: “News... read more
Men who have anal sex with men (MSM) are more likely to get anal HPVthan men who only have sex... read more